Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Sankyo, Daiichi to Enhance Independent Marketing in Global Market
May 30, 2005
- BUSINESS NEWS IN BRIEF
May 30, 2005
- NEW PRODUCTS
May 30, 2005
- Flat Price System Is Unsuitable in Japan: Dr Okuda
May 30, 2005
- REGULATORY NEWS IN BRIEF
May 30, 2005
- Central, Local Gov't Must Cooperate Closely to Effectively Implement Amended PAL
May 30, 2005
- TPOICS
May 30, 2005
- Industry Appreciates Improvements Made by National Hospitals to Facilitate Clinical Trials
May 30, 2005
- Astellas Pharma: Sales of \862 Bil. in 1st Settlement
May 30, 2005
- R&D NEWS IN BRIEF
May 30, 2005
- Eisai: Aricept, Pariet Drive Growth in Sales, Profits
May 30, 2005
- MEDICAL DEVICE NEWS IN BRIEF
May 30, 2005
- NEW PRODUCTS
May 23, 2005
- Sankyo: Mevalotin Patent Expiration Hits Business
May 23, 2005
- R&D NEWS IN BRIEF
May 23, 2005
- MPC Aims at Becoming Global Pharma through Holding Company
May 23, 2005
- Spiriva Can Cut COPD Treatment Cost by ¥59 Bil. a Year
May 23, 2005
- Discovering 2 to 3 New Drug Candidates a Year "Achievable": Tanabe Seiyaku
May 23, 2005
- PMDA to Restart Receiving Applications for Clinical Trial Consultation
May 23, 2005
- Santen: Domestic Market Spurs Growth in Sales
May 23, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…